NASDAQ:ACHV Achieve Life Sciences (ACHV) Stock Price, News & Analysis $4.60 +0.03 (+0.66%) Closing price 05/21/2026 04:00 PM EasternExtended Trading$4.68 +0.08 (+1.63%) As of 05/21/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Achieve Life Sciences Stock (NASDAQ:ACHV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Achieve Life Sciences alerts:Sign Up Key Stats Today's Range$4.45▼$4.7550-Day Range$2.65▼$5.9952-Week Range$2.00▼$6.15Volume840,824 shsAverage Volume1.27 million shsMarket Capitalization$244.86 millionP/E RatioN/ADividend YieldN/APrice Target$14.67Consensus RatingBuy Company Overview Achieve Life Sciences, Inc. (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement. Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings. The compound has been used by more than 35,000 patients outside the United States since the 1960s. Achieve is currently conducting a pivotal Phase 3 trial, known as ORCA-2, in the U.S., following receipt of Fast Track designation from the U.S. Food and Drug Administration. Positive outcomes from these studies could form the basis for a New Drug Application submission. The company holds worldwide rights to cytisinicline, having in-licensed the compound from Sopharma AD. Headquartered in Vancouver, British Columbia, Achieve Life Sciences operates primarily in North America while exploring strategic partnerships for ex-U.S. commercialization. The company’s global strategy leverages a combination of direct development efforts and collaboration agreements to broaden patient access to cytisinicline. Achieve Life Sciences is led by President and Chief Executive Officer Carole L. Spagnoletti, a seasoned biopharmaceutical executive with over 25 years of experience in clinical development and regulatory affairs. The senior management team comprises professionals with deep expertise in drug development, regulatory strategy, and commercialization planning, all focused on bringing a new smoking cessation therapy to market. AI Generated. May Contain Errors. Read More Achieve Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreACHV MarketRank™: Achieve Life Sciences scored higher than 62% of companies evaluated by MarketBeat, and ranked 329th out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingBuy Consensus RatingAchieve Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAchieve Life Sciences has a consensus price target of $14.67, representing about 218.8% upside from its current price of $4.60.Amount of Analyst CoverageAchieve Life Sciences has only been the subject of 3 research reports in the past 90 days.Read more about Achieve Life Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Achieve Life Sciences are expected to grow in the coming year, from ($0.91) to ($0.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Achieve Life Sciences is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Achieve Life Sciences is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAchieve Life Sciences has a P/B Ratio of 23.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Achieve Life Sciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.34% of the float of Achieve Life Sciences has been sold short.Short Interest Ratio / Days to CoverAchieve Life Sciences has a short interest ratio ("days to cover") of 2.66, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Achieve Life Sciences has recently increased by 0.66%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAchieve Life Sciences does not currently pay a dividend.Dividend GrowthAchieve Life Sciences does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.75 News SentimentAchieve Life Sciences has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Achieve Life Sciences this week, compared to 4 articles on an average week.Search InterestOnly 11 people have searched for ACHV on MarketBeat in the last 30 days. This is a decrease of -48% compared to the previous 30 days.MarketBeat Follows9 people have added Achieve Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Achieve Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders3.00% of the stock of Achieve Life Sciences is held by insiders.Percentage Held by Institutions33.52% of the stock of Achieve Life Sciences is held by institutions.Read more about Achieve Life Sciences' insider trading history. Receive ACHV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Achieve Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACHV Stock News HeadlinesAchieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline TreatmentMay 19 at 2:15 PM | globenewswire.comAchieve Life Sciences (NASDAQ:ACHV) Stock Rating Upgraded by Wall Street ZenMay 17, 2026 | americanbankingnews.comYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.97 on his website. The download link is temporary, so this is your window to save a copy before it expires. Once it's gone, you'll need to pay full price. | Profits Run (Ad)Achieve Life Sciences (ACHV) price target decreased by 14.04% to 12.82May 14, 2026 | msn.comAchieve Life Sciences: 'Hold' On Expected CRL Cytisinicline And Q4 2026 NDA ResubmissionMay 13, 2026 | seekingalpha.comAchieve Life Sciences Inc (ACHV) Q1 2026 Earnings Call Highlights: Strategic Financing and ...May 13, 2026 | finance.yahoo.comAchieve Life Sciences, Inc. (ACHV) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comAchieve Life Sciences Announces Senior Leadership Appointments to Drive Commercialization of CytisiniclineMay 12, 2026 | quiverquant.comQSee More Headlines ACHV Stock Analysis - Frequently Asked Questions How have ACHV shares performed this year? Achieve Life Sciences' stock was trading at $4.97 at the beginning of the year. Since then, ACHV stock has decreased by 7.4% and is now trading at $4.60. How were Achieve Life Sciences' earnings last quarter? Achieve Life Sciences, Inc. (NASDAQ:ACHV) announced its earnings results on Tuesday, May, 12th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.11. Read the conference call transcript. When did Achieve Life Sciences' stock split? Achieve Life Sciences's stock reverse split before market open on Friday, July 31st 2020.The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Achieve Life Sciences' major shareholders? Top institutional investors of Achieve Life Sciences include Bank of America Corp DE (0.13%), Manchester Financial Inc. (0.12%), Next Capital Management LLC (0.07%) and Renaissance Technologies LLC (0.05%). Insiders that own company stock include Thomas Braxton King, Richard Alistair Stewart, Mark K Oki, Cindy Jacobs, Jaime Xinos, John Bencich and Jerry Wan. View institutional ownership trends. How do I buy shares of Achieve Life Sciences? Shares of ACHV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Achieve Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Achieve Life Sciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Meta Platforms (META), Moderna (MRNA), Netflix (NFLX) and Visa (V). Company Calendar Last Earnings5/12/2026Today5/22/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 ACHV's financial health is in the Green zone, according to TradeSmith. ACHV has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryBiotechnology Current SymbolNASDAQ:ACHV CIK949858 Webachievelifesciences.com Phone(604) 210-2217Fax425-686-1600Employees20Year Founded1995Price Target and Rating Average Price Target for Achieve Life Sciences$14.67 High Price Target$19.00 Low Price Target$12.00 Potential Upside/Downside+218.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$54.65 million Net MarginsN/A Pretax MarginN/A Return on Equity-193.49% Return on Assets-111.88% Debt Debt-to-Equity Ratio0.87 Current Ratio2.62 Quick Ratio2.62 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book23.00Miscellaneous Outstanding Shares53,230,000Free Float51,637,000Market Cap$244.86 million OptionableOptionable Beta2.25 Social Links 10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:ACHV) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredI had never heard of this 1888 accountAn investment account dating back to 1888 has quietly delivered average annual returns of 29% over the last 25...The Oxford Club | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSneak Peek: Wall Street’s Little Black BookTom Busby, pro trader and CEO of the Diversified Trading Institute, spent years building a collection of what ...DTI Trader | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achieve Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Achieve Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
